Oridonin Relieves Angiotensin II-Induced Cardiac Remodeling via Inhibiting GSDMD-Mediated Inflammation

Oridonin inhibits IL-1β-induced inflammation in human osteoarthritis chondrocytes by activating PPAR-γ

(2019) Tao Jia et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

Oridonin protects LPS-induced acute lung injury by modulating Nrf2-mediated oxidative stress and Nrf2-independent NLRP3 and NF-κB pathways

(2019) Huahong Yang et al.   Cell Communication and Signaling

Oridonin inhibits LPS-induced inflammation in human gingival fibroblasts by activating PPARγ

(2019) Tianliang Yu et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

NLRP3 inflammasome

(2019) Marina Sokolova et al.   JOURNAL OF CARDIOVASCULAR PHARMACOLOGY

NLRP3 Inflammasome Promotes Myocardial Remodeling During Diet-Induced Obesity

(2019) Marina Sokolova et al.   Frontiers in Immunology

α-NETA induces pyroptosis of epithelial ovarian cancer cells through the GSDMD/caspase-4 pathway

(2019) Lianqiao Qiao et al.   FASEB JOURNAL

Oridonin, A natural diterpenoid, protected NGF-differentiated PC12 cells against MPP+- and kainic acid-induced injury

(2019) Kuan-Ho Lin et al.   FOOD AND CHEMICAL TOXICOLOGY

microRNA‐132 inhibits cardiomyocyte apoptosis and myocardial remodeling in myocardial infarction by targeting IL‐1β

(2019) Zonglei Zhao et al.   JOURNAL OF CELLULAR PHYSIOLOGY

Oridonin inhibits vascular inflammation by blocking NF-κB and MAPK activation

(2018) Weichen Huang et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Downregulation of gasdermin D promotes gastric cancer proliferation by regulating cell cycle-related proteins

(2018) Wei Jie Wang et al.   Journal of Digestive Diseases

Effect of ingredients from Chinese herbs on enterovirus D68 production

(2018) Xiangling Meng et al.   PHYTOTHERAPY RESEARCH

Chemotherapy drugs induce pyroptosis through caspase-3 cleavage of a gasdermin

(2017) Yupeng Wang et al.   NATURE

Pore formation by GSDMD is the effector mechanism of pyroptosis

(2016) Moritz M Gaidt et al.   EMBO JOURNAL

GSDMD membrane pore formation constitutes the mechanism of pyroptotic cell death

(2016) Lorenzo Sborgi et al.   EMBO JOURNAL

Pentoxifylline Ameliorates Cardiac Fibrosis, Pathological Hypertrophy, and Cardiac Dysfunction in Angiotensin II-induced Hypertensive Rats

(2016) Xiyan Zhang et al.   JOURNAL OF CARDIOVASCULAR PHARMACOLOGY

Erratum: Pore-forming activity and structural autoinhibition of the gasdermin family

(2016) Jingjin Ding et al.   NATURE

GsdmD p30 elicited by caspase-11 during pyroptosis forms pores in membranes

(2016) Robin A. Aglietti et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

NADPH Oxidase 4 Induces Cardiac Fibrosis and Hypertrophy Through Activating Akt/mTOR and NF B Signaling Pathways

(2015) Q. D. Zhao et al.   CIRCULATION

Dual Activation of TRIF and MyD88 Adaptor Proteins by Angiotensin II Evokes Opposing Effects on Pressure, Cardiac Hypertrophy, and Inflammatory Gene ExpressionNovelty and Significance

(2015) Madhu V. Singh et al.   HYPERTENSION

Oridonin's therapeutic effect: Suppressing Th1/Th17 simultaneously in a mouse model of Crohn's disease

(2015) Shubei Wang et al.   JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY

Contractile Function During Angiotensin-II Activation

(2015) Min Zhang et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Caspase-11 cleaves gasdermin D for non-canonical inflammasome signalling

(2015) Nobuhiko Kayagaki et al.   NATURE

Cleavage of GSDMD by inflammatory caspases determines pyroptotic cell death

(2015) Jianjin Shi et al.   NATURE

Mitochondrial NLRP3 Protein Induces Reactive Oxygen Species to Promote Smad Protein Signaling and Fibrosis Independent from the Inflammasome

(2014) Nathan A. Bracey et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Cardiomyocyte culture — an update on the in vitro cardiovascular model and future challenges

(2013) Sreejit Parameswaran et al.   CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY

NLRP3 Inflammasomes Show High Expression in Aorta of Patients with Atherosclerosis

(2013) Fei Zheng et al.   Heart Lung and Circulation

Signal Regulatory Protein-α Protects Against Cardiac Hypertrophy Via the Disruption of Toll-Like Receptor 4 Signaling

(2013) Ding-Sheng Jiang et al.   HYPERTENSION

Interferon-γ Signaling Inhibition Ameliorates Angiotensin II–Induced Cardiac Damage

(2012) Lajos Markó et al.   HYPERTENSION

CIKS (Act1 or TRAF3IP2) mediates Angiotensin-II-induced Interleukin-18 expression, and Nox2-dependent cardiomyocyte hypertrophy

(2012) Anthony J. Valente et al.   JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY

Activation of the renal Na+:Cl- cotransporter by angiotensin II is a WNK4-dependent process

(2012) M. Castaneda-Bueno et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The role of monocytes and inflammation in the pathophysiology of heart failure

(2011) Benjamin J. Wrigley et al.   EUROPEAN JOURNAL OF HEART FAILURE

New Take on the Role of Angiotensin II in Cardiac Hypertrophy and Fibrosis

(2011) Mazen Kurdi et al.   HYPERTENSION

Oridonin: An active diterpenoid targeting cell cycle arrest, apoptotic and autophagic pathways for cancer therapeutics

(2011) Chun-yang Li et al.   INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY

Cardiac-Specific Activation of Angiotensin II Type 1 Receptor–Associated Protein Completely Suppresses Cardiac Hypertrophy in Chronic Angiotensin II–Infused Mice

(2010) Hiromichi Wakui et al.   HYPERTENSION

Interferon-γ and the Interferon-Inducible Chemokine CXCL10 Protect Against Aneurysm Formation and Rupture

(2009) Victoria L. King et al.   CIRCULATION